Brokerages Set Ascendis Pharma A/S (NASDAQ:ASND) Price Target at $243.36

Key Points

• Analysts have assigned Ascendis Pharma A/S a consensus rating of "Buy", with fifteen ratings firms covering the stock.
• The average 12-month target price for Ascendis Pharma is $243.36, with some analysts raising their targets significantly, including Citigroup's increase to $290.00.
• In its latest quarterly earnings report, Ascendis Pharma exceeded expectations by posting a revenue of $216.28 million against an anticipated $163.17 million.

Shares of Ascendis Pharma A/S (NASDAQ:ASND - Get Free Report) have been given an average rating of "Buy" by the fifteen analysts that are currently covering the firm, MarketBeat Ratings reports. Fifteen analysts have rated the stock with a buy recommendation. The average 1-year price objective among analysts that have issued a report on the stock in the last year is $243.3571.

A number of research analysts recently issued reports on the company. Royal Bank Of Canada lifted their target price on Ascendis Pharma A/S from $210.00 to $230.00 and gave the stock an "outperform" rating in a report on Friday, August 8th. Wedbush lifted their price target on Ascendis Pharma A/S from $212.00 to $220.00 and gave the stock an "outperform" rating in a research note on Friday, August 8th. Morgan Stanley started coverage on Ascendis Pharma A/S in a research note on Thursday, July 3rd. They issued an "overweight" rating and a $250.00 price target on the stock. JPMorgan Chase & Co. lifted their price target on Ascendis Pharma A/S from $254.00 to $260.00 and gave the stock an "overweight" rating in a research note on Tuesday, August 19th. Finally, Cantor Fitzgerald lifted their price target on Ascendis Pharma A/S from $200.00 to $203.00 and gave the stock an "overweight" rating in a research note on Friday, August 8th.

Ascendis Pharma A/S Price Performance

Shares of ASND traded down $3.65 during trading hours on Friday, reaching $193.01. 378,647 shares of the company's stock traded hands, compared to its average volume of 567,252. The firm has a market capitalization of $11.81 billion, a price-to-earnings ratio of -37.41 and a beta of 0.41. Ascendis Pharma A/S has a twelve month low of $111.09 and a twelve month high of $199.99. The business's fifty day simple moving average is $179.38 and its two-hundred day simple moving average is $164.88.

Ascendis Pharma A/S (NASDAQ:ASND - Get Free Report) last issued its quarterly earnings results on Thursday, August 7th. The biotechnology company reported ($0.93) EPS for the quarter, beating analysts' consensus estimates of ($1.42) by $0.49. The business had revenue of $216.28 million for the quarter, compared to analyst estimates of $163.17 million. On average, equities research analysts expect that Ascendis Pharma A/S will post -4.34 EPS for the current year.

Hedge Funds Weigh In On Ascendis Pharma A/S

Several institutional investors and hedge funds have recently modified their holdings of the stock. Point72 Asia Singapore Pte. Ltd. acquired a new position in Ascendis Pharma A/S in the 4th quarter worth about $28,000. Compagnie Lombard Odier SCmA bought a new stake in shares of Ascendis Pharma A/S in the 2nd quarter valued at approximately $39,000. First Horizon Advisors Inc. bought a new position in Ascendis Pharma A/S during the second quarter valued at approximately $41,000. Hantz Financial Services Inc. lifted its stake in Ascendis Pharma A/S by 291.1% in the second quarter. Hantz Financial Services Inc. now owns 352 shares of the biotechnology company's stock valued at $61,000 after acquiring an additional 262 shares during the last quarter. Finally, Brooklyn Investment Group boosted its holdings in Ascendis Pharma A/S by 332.9% in the first quarter. Brooklyn Investment Group now owns 355 shares of the biotechnology company's stock worth $55,000 after purchasing an additional 273 shares in the last quarter.

About Ascendis Pharma A/S

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.